STAT Plus: We have answers to some of biotech’s burning questions for 2019 — and some new issues to watch
So, how’s it going?
Last January, we compiled a list of “burning questions” for a group of the largest and most closely followed biotech companies. Answers to these questions — encompassing financial performance, clinical trial milestones, and regulatory approvals — can make or break a company’s performance during the year.
